netFormulary NHS
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

For the most up to date list of agents funded by the Cancer Drugs Fund, please see Cancer Drug Fund list

 Details...
08.01.05  Expand sub section  Other antineoplastic drugs
Abemaciclib (Verzenios®)
View adult BNF View SPC online View childrens BNF
Formulary
Red

In line with NICE

 
Link  Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [TA579]
Link  NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Bosutinib (Bosulif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
  • In line with NICE
  • Hospital only- NHSE commissioned 
  • Link  TA401: Bosutinib for previously treated chronic myeloid leukaemia
       
    Brigatinib (Alunbrig®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    In line with NICE

     
    Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
       
    Carfilzomib (Kyprolis®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE TA457: Carfilzomib for previously treated multiple myeloma
       
    Cemiplimab
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    Use in line with NICE

     
    Link  NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
       
    Ceritinib Black Triangle (Zykadia®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    NHS England

    In line with NICE

     
    Link  NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
       
    Dabrafenib with Trametinib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    In line with NICE

     
    Link  NICE TA 544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
       
    Daratumumab (Darzalex ®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    In line with NICE

     
    Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
    Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
       
    Dupilumab
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    CCG
    Homecare

    In line with NICE

     
    Link  NICE TA 534: Dupilumab for treating moderate to severe atopic dermatitis
       
    Durvalumab
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    In line with NICE

     
    Link  Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [TA578]
       
    Encorafenib with binimetinib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red

    In line with NICE

     
    Link  NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
       
    Cytotoxic Drug Eribulin (Halaven®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • In line with NICE
  • Hospital only- NHSE commissioned 
  • Link  TA423:Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
       
    Ibrutinib (Imbruvica®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    NHS England
    • In line with NICE
    • Hospital only- NHSE commissioned
     
    Link  NICE TA 502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
    Link  NICE TA 491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
       
    Idelalisib (Zydelig®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • NHS England is responsible commissioner for its use in chronic lymphocytic leukaemia(as per NICE TA 359)
     
  • Link  NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia (Oct 2015)
       
    Ixazomib
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    Cancer Drugs Fund
    NHS England

    In line with NICE

    Hospital only - NHSE commissioned.

     
    Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
       
    LenvatinibBlack Triangle (Kisplyx ®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    NHS England

    In line with NICE

     
    Link  NICE TA 498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
    Link  NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
    Link  NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
       
    Midostaurin  (Rydapt® )
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    In line with NICE

    NHSE commissioned

     
    Link  NICE TA523:Midostaurin for untreated acute myeloid leukaemia
       
    Nintedanib (Vargatef ®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    • Hospital only- NHSE commissioned
    • In line with NICE and available from day 91 following publication of TA.
     
    Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
       
    Niraparib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England
     
    Link  NICE TA 528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
       
    Niraparib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England
     
       
    Olaparib (Lynparza ® View adult BNF View SPC online View childrens BNF Formulary
    Red
    High Cost Medicine
    • Hospital only- NHSE commissioned
    • In line with NICE and available from day 91 following publication of TA.
     
    Link  NICE TA381: Olaparib for the maintenance treatment of ovarian, fallopian tube and peritoneal cancer
    Link  NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
       
    Palbociclib (Ibrance®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • In line with NICE
  • Hospital only - NHSE commissioned 
  • Link  NICE TA 495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
       
    Panobinostat (Farydak®Restricted Item View adult BNF View SPC online View childrens BNF Formulary
    Red
    High Cost Medicine
  • Hospital only- NHSE commissioned
  • In line with NICE and available from day 91 following publication of TA.
     
  • Link  NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
       
    Pegaspargase (Oncaspar®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
  • Hospital only- NHSE Commissioned
  • In line with NICE and available from day 91 following publication of TA.
     
  • Link  NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia-
       
    Pembrolizumab (Keytruda®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
  • NHS England is responsible commissioner in line with NICE (see links below)
     
  • Link  NICE TA 557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
    Link  NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
    Link  NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
    Link  NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
    Link  NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab (Nov 2015)
    Link  NICE TA 540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
    Link  NICE TA 600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
    Link  NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
    Link  NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (Oct 2015)
       
    Ribociclib (Kisqali®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • In line with NICE
  • Hospital only - NHSE commissioned 
  • Link  NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
    Link  NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
       
    Ruloxitinib (Jakavi® View adult BNF View SPC online View childrens BNF Formulary
    Red
  • Hospital only- NHS England is responsible commissioner
  • In line with NICE and available from day 91 following publication of TA (see links below)
     
  • Link  NICE TA 386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
       
    Talimogene laherparepvec Restricted Item  (Imlygic®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • Hospital only- NHS E commissioned
  • In line with NICE and available from day 91 following publication of TA (see link below)
     
  • Link  NICE TA410: Unresectable metastatic melanoma- Talimogene laherparepvec
       
    Tisagenlecleucel (Kymriah®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
    NHS England

    In line with NICE

     
    Link  NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
    Link  NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
       
    Osimertinib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    In line with NICE 
    Link  TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
       
    Venetoclax (Venclyxto® )
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
  • In line with NICE 
  • Link  NICE TA 487: Venetoclax for treating chronic lymphocytic leukaemia
    Link  NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
       
    08.01.05  Expand sub section  Amsacrine
    08.01.05  Expand sub section  Arsenic trioxide
    Cytotoxic Drug Arsenic Trioxide (Trisenox®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England
    • In line with NICE
     
    Link  NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
       
    08.01.05  Expand sub section  Bevacizumab
    Bevacizumab
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
  • Funding available through Cancer Drugs Fund (CDF) for indications listed in CDF list.
  • Click here to access latest CDF list.  
  • Link  NICE TA212: Colorectal cancer (metastatic) - bevacizumab
    Link  NICE TA214: Breast Cancer with taxane
    Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
    Link  NICE TA263: Breast cancer with capecitabine
    Link  NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
    Link  NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
       
    08.01.05  Expand sub section  Bexarotene to top
    Bexarotene
    (capsules)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    08.01.05  Expand sub section  Bortezomib
    Bortezomib (Velcade®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
  • In line with NICE 
  • Link  NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
    Link  NICE TA311: Multiple myeloma - bortezomib (induction therapy
    Link  NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
    Link  NICE TA129: Multiple myeloma - bortezomib
       
    08.01.05  Expand sub section  Brentuximab vedotin
    Brentuximab vedotin (Adcetris®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
    • In line with NICE
     
    Link  NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
    Link  NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
    Link  NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
       
    08.01.05  Expand sub section  Cetuximab
    Cetuximab (Erbitux®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
    Link  NICE TA145: Head and neck cancer - cetuximab
    Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
    Link  NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
    Link  NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
       
    08.01.05  Expand sub section  Crisantaspase
    Crisantaspase (Erwinase®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    08.01.05  Expand sub section  Dacarbazine and Temozolomide to top
    Cytotoxic Drug Dacarbazine
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    Cytotoxic Drug Temozolomide (Temodal®)
    (capsules)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
    Link  NICE TA23: Brain cancer - temozolomide
       
    08.01.05  Expand sub section  Erlotinib
    Erlotinib (Tarceva® )
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • in line with NICE and available from day 91 following publication of TA. 
  • Link  NICE TA374: Lung cancer (non-small cell, locally advanced or metastatic)- erlotinib and gefitinib after prior chemotherapy
    Link  NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
    Link  NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
       
    08.01.05  Expand sub section  Hydroxycarbamide
    Cytotoxic Drug Hydroxycarbamide
    View adult BNF View SPC online View childrens BNF
    Formulary
    Amber
  • For myeloproliferative disorders.
  • Supported by an ESCA (in development)

  • For use in sickle cell- see chapter 9
     
  •    
    08.01.05  Expand sub section  Ipilimumab
    Ipilimumab (Yervoy®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
    Link  NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
       
    08.01.05  Expand sub section  Mitotane
    Mitotane (Lysodren®)
    (tablets)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    08.01.05  Expand sub section  Panitumumab to top
    Panitumumab (Vectibix®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
    Link  NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
       
    08.01.05  Expand sub section  Pentostatin
    08.01.05  Expand sub section  Platinum compounds
    Cytotoxic Drug Oxaliplatin
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
       
    08.01.05  Expand sub section  Porfimer sodium and temoporfin
    08.01.05  Expand sub section  Procarbazine
    Cytotoxic Drug Procarbazine
    (capsules)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    08.01.05  Expand sub section  Protein kinase inhibitors to top
    Afatinib (Giotrif®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • In line with NICE 
  • Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
       
    Alectinib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    In line with NICE

     
    Link  Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
       
    Cabozantinib (Cabometyx®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
    Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
       
    Crizotinib (Xalkori®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
  • Hospital only- NHSE commissioned
  • In line with NICE 
  • Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA406:Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
    Link  NICE TA 529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
       
    Dacomitinib
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    Use in line with NICE

     
    Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
       
    Dasatinib (Sprycel®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    Cancer Drugs Fund
    In line with NICE 
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
       
    Everolimus (Afinitor®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE
    Hospital only-NHSE commissioned 
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
    Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
    Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
       
    Everolimus (Votubia®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
    Gefitinib (Iressa®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
       
    Cytotoxic Drug Imatinib (Glivec®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    in line with NICE 
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
    Link  NICE TA326: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
    Link  NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib. NOT RECOMMENDED
    Link  NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
       
    Lapatinib (Tyverb®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
       
    Nilotinib (Tasigna®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    In line with NICE 
    Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
    Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
       
    Pazopanib (Votrient®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
    Link  NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
       
    Ponatinib (Iclusig®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE TA451:Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
       
    Regorafenib (Stivarga® )
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
  • In line with NICE
  • NHS E commissioned 
  • Link  NICE TA 555:Regorafenib for previously treated advanced hepatocellular carcinoma
    Link  NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
       
    Sorafenib (Nexavar®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
       
    Sunitinib (Sutent®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
    Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
    Link  NICE TA178: Renal cell carcinoma
    Link  NICE TA169: Renal cell carcinoma - sunitinib
       
    Cytotoxic Drug Temsirolimus (Torisel®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    Cancer Drugs Fund
     
    Link  NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
    Link  NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
       
    Tivozanib (Fotivda®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    NHS England

    In line with NICE

     
    Link  NICE TA512:Tivozanib for treating advanced renal cell carcinoma
       
    Vemurafenib (Zelboraf®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
    Link  NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
       
    08.01.05  Expand sub section  Taxanes
    Cytotoxic Drug Cabazitaxel (Jevtana®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
  • In line with NICE 
  • Link  NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (updated Aug 2016)
       
    Cytotoxic Drug Docetaxel
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
    In line with NICE 
    Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
    Link  NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
       
    Cytotoxic Drug Paclitaxel
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
  • In line with NICE  
  • Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
    Link  NICE TA55: Ovarian cancer - paclitaxel (review)
       
    Cytotoxic Drug Paclitaxel - Albumin Bound Formulation (Abraxane®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
    High Cost Medicine
  • In line with NICE 
  • Link  NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
       
    08.01.05  Expand sub section  Topoisomerase I inhibitors
    Cytotoxic Drug Topotecan (Hycamtin®)
    View adult BNF View SPC online View childrens BNF
    Restricted Drug Restricted
    Red
  • In line with NICE 
  • Link  NICE TA183: Cervical cancer (recurrent) - topotecan
    Link  NICE TA184: Lung cancer (small-cell) - topotecan
    Link  NICE TA389: Ovarian cancer (recurrent) - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine
       
    08.01.05  Expand sub section  Trabectedin
    08.01.05  Expand sub section  Trastuzumab
    Cytotoxic Drug Pertuzumab (Perjeta®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    High Cost Medicine
    In line with NICE
     
    Link  NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
    Link  NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
    Link  TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
       
    Cytotoxic Drug Trastuzumab (Herceptin®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    In line with NICE 
    Link  NICE NG101: Early and locally advanced breast cancer: diagnosis and management
    Link  NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
    Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
    Link  NICE TA34: Breast cancer (advanced)- trastuzumab
       
    Cytotoxic Drug Trastuzumab emtansine (Kadcyla®)
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
    In line with NICE 
    Link  NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
       
    08.01.05  Expand sub section  Tretinoin to top
    08.01.05  Expand sub section  Vismodegib
     ....
     Non Formulary Items
    Cytotoxic Drug  Amsacrine  (Amsidine®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Axitinib  (Inlyta®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Carboplatin  (Paraplatin®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Cytotoxic Drug  Irinotecan Hydrochloride  (Campto®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary

    Negative NICE TA

    Link  Negative NICE TA 307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
    Link  Negative NICE TA 440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
     
    Oxaliplatin  (Eloxatin®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Cytotoxic Drug  Pentostatin  (Nipent®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Porfimer Sodium

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Temoporfin  (Foscan®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Cytotoxic Drug  Trabectedin  (Yondelis®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
    Link  NICE TA185: Soft tissue sarcoma - trabectedin
    Link  NICE TA222- ovarian cancer
     
    Tretinoin

    View adult BNF View SPC online View childrens BNF
    Non Formulary
    Red
     
    Cytotoxic Drug  Vandetanib  (Caprelsa®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
    Link  NICE TA550: Vandetanib for treating medullary thyroid cancer
     
    Cytotoxic Drug  Vismodegib  (Erivedge®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary

    Negative NICE TA

    Link  Negative NICE TA 489: Vismodegib for treating basal cell carcinoma
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Prescribing in children

    The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.

    The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.

      

    Green

    Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.  

    Amber

    Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.

    Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.   

    Red

    Medicines for initiation and maintenance prescribing by Specialists only  

    Black

    Non-formulary medicines- medicines not recommended for routine primary care prescribing.  

    Grey

    Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.  

    netFormulary